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Shiga toxin-producing Escherichia coli (STEC) is a leading cause of childhood renal
disease Hemolytic Uremic Syndrome (HUS). The involvement of renal cytokines and
chemokines is suspected to play a critical role in disease progression. In current article,
we tested the hypothesis that NKT cells are involved in Stx2-induced pathology in vivo.
To address this hypothesis we compared Stx2 toxicity in WT and CD1 knockout (KO)
mice. In CD1KO mice, which lack natural killer T (NKT) cells, Stx2-induced pathologies
such as weight loss, renal failure, and death were delayed. In WT mice, Stx2-specific
selective increase in urinary albumin occurs in later time points, and this was also delayed
in NKT cell deficient mice. NKT cell-associated cytokines such as IL-2, IL-4, IFN-γ, and
IL-17 were detected in kidney lysates of Stx2-injected WT mice with the peak around
36 h after Stx2 injection. In CD1KO, there was a delay in the kinetics, and increases in
these cytokines were observed 60 h post Stx2 injection. These data suggest that NKT
cells accelerate Stx2-induced pathology in mouse kidneys. To determine the mechanism
by which NKT cells promote Stx2-associated disease, in vitro studies were performed
usingmurine renal cells. We found that murine glomerular endothelial cells and podocytes
express functional CD1d molecules and can present exogenous antigen to NKT cells.
Moreover, we observed the direct interaction between Stx2 and the receptor Gb3 on
the surface of mouse renal cells by 3D STORM-TIRF which provides single molecule
imaging. Collectively, these data suggest that Stx2 binds to Gb3 on renal cells and leads
to aberrant CD1d-mediated NKT cell activation. Therefore, strategies targeting NKT cells
could have a significant impact on Stx2-associated renal pathology in STEC disease.
Keywords: Shiga toxin, Escherichia coli, hemolytic uremic syndrome, natural killer T cell, cytokines, single
molecule imaging, STORM-TIRF, mouse models
Introduction
Shiga toxin-producing Escherichia coli (STEC) causes renal disease, hemolytic uremic syndrome
(HUS) (Karmali et al., 1985). HUS is a leading cause of renal failure in otherwise healthy
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children and Shiga toxin type 2 (Stx2) is often associated with
severe symptoms of STEC infection (Lopez et al., 1989; Ostroff
et al., 1989). In STEC patients, an increase in white blood cells
(WBC) namely neutrophils and monocytes, is often associated
with HUS (Gianantonio et al., 1973; Ryan et al., 1986; Martin
et al., 1990; Robson et al., 1993; Su and Brandt, 1995; Perez et al.,
1998; Dervenoulas et al., 2000; Ake et al., 2005; Fernandez et al.,
2005; Ramos et al., 2007). Serum cytokines such as IL-6, IL-8, IL-
10 and TNFα are often found increased in STEC-HUS (Murata
et al., 1998; Proulx et al., 1998; Shimizu et al., 2012; Valles et al.,
2012). Similarly, in animal models, Shiga toxins-injected animals
showed blood profiles such as an increase in neutrophils (Fer-
nandez et al., 2006; Keepers et al., 2006; Sauter et al., 2008),
IL-6 and TNFα (Sauter et al., 2008; Stearns-Kurosawa et al.,
2010). In addition, several animal model studies have found a
variety of cytokines and chemokines are produced in the kid-
ney (Keepers et al., 2007; Roche et al., 2007; Sauter et al., 2008;
Zanchi et al., 2008; Petruzziello-Pellegrini et al., 2012; Stearns-
Kurosawa et al., 2013). The mechanism by which Shiga toxins
rapidly induce many types of cytokines and chemokines, with-
out a strong inflammatory factor like lipopolysaccharide, is not
precisely understood.
NKT cells are a small population of immune cells in blood
(0.2–0.5% in mouse and 0.01—0.5% in human (Berzins et al.,
2011), however they can serve as strong inducers of inflamma-
tion. NKT cells can rapidly secrete a large amount of cytokines,
including Th1, Th2, and Th17 cytokines (Berzins et al., 2011),
and these cytokines activate other immune cells (Matsuda et al.,
2008). Unlike classic T cells, NKT cells recognize glycolipid anti-
gens presented by CD1d molecules (Kawano et al., 1997). There
are two types of NKT cells. Type I NKT cells express a semi-
invariant TCR α chain Vα24Jα18 (human) or Vα14Jα18 (mouse)
and can be activated with alpha-galactosylceramide (αGC). Type
II NKT cells express various TCR α chains and are restricted
to CD1d, but cannot be activated with αGC. Mice lacking CD1
(CD1KO) are both type I and II NKT cell deficient. The involve-
ment of CD1d-restricted NKT cells in STEC-mediated disease
has never been described. We compared WT and CD1KO mice
disease progression following Stx2 injection and observed that
CD1KO mice had delayed Stx2-induced pathology.
Historically, it was controversial whether murine glomerular
cells such as podocytes and endothelial cells interact with Stx2
for both reports that showed interaction (Morigi et al., 2006) and
no interaction (Psotka et al., 2009) existed. On the other hand,
human glomerular endothelial cells and podocytes are known to
express Gb3 and are sensitive to Shiga toxins (Psotka et al., 2009).
This has been a problem with the murine model in regards to
the similarity to human pathology. We tested direct interaction
of Stx2 with murine glomerular cell surface Gb3 in vitro using
a sensitive imaging system, STochastic Optical Reconstruction
Microscopy (STORM)—Total Internal Reflection Fluorescence
microscope (TIRF) that has ability to image single molecules
(Smyth and Shaw, 2008; Dempsey et al., 2011; Liesche et al.,
2013). Also, using cellular assays, we tested the ability of Stx2-pre-
treated glomerular cells to activate NKT cells in vitro. Here for
the first time we demonstrate that Stx2 induces CD1d-mediated
activation of NKT cells via glomerular cells.
Materials and Methods
Animals
Male C57BL/6 (wild type, WT) mice weighing 22 to 24 g were
purchased from Charles River Laboratories (Wilmington, MA,
USA). Male CD1.1−/− (CD1KO) mice of the matched age were
maintained in Webb lab (Carnaud et al., 1999; Park et al., 1999;
Hua et al., 2011). Mice were housed in a 12 h/12 h light and
dark cycle and given access to food and water ad libitum. Mice
were injected intraperitoneally 250 ng/kg Stx2 (two times the
50% lethal dose). At this dose of Stx2, 50% of WT mice die at
approximately 72 h, and 100% die by 96 h (Figure 1). This dose
was chosen based on previous studies with our mouse model
of HUS (Keepers et al., 2006). Weight and survival were moni-
tored every 12 h using five mice per strain. In the different set of
experiment, at selected time points after injection, three mice per
time point were euthanized by CO2 inhalation and kidneys were
removed. Kidneys collected at 0 h (prior to Stx2 injection) were
used for controls. Kidneys were processed for enzyme-linked
immunosorbent assay (ELISA) as described below. Mouse blood
was withdrawn into a 0.5M of sodium ethylenediaminetetraac-
etate (Na2EDTA) wetted needle and syringe from their heart at
each time point to isolate plasma for blood urea nitrogen (BUN)
assay. Blood from 0 h (prior to Stx2 injection) animals were used
as controls. All animal procedures were performed in accor-
dance with University of Maryland School of Medicine Animal
Care and Use Committee policies (animal use protocol number
0811012).
Cell Culture
Vero cells were purchased from American Type Culture Col-
lection (ATCC, Manassas, VA) and maintained in RPMI1640
media (Life Technologies, Grand Island, NY) supplemented
with 10% fetal bovine serum (HyClone/ThermoFisher Scien-
tific, Waltham, MA), 2mM L-glutamine (Cellgro/Mediatech,
Manassas, VA) and 100 U/ml penicillin and 100µg/ml strepto-
mycin (Life Technologies). Conditionally immortalized murine
podocyte andmurine glomerular endothelial cells were described
previously (Mundel et al., 1997; Akis and Madaio, 2004; Psotka
et al., 2009) and cultured in RPMI1640 supplemented with 10%
FBS, 2mM L-glutamine, 100U/ml penicillin, 100µg/ml strepto-
mycin and 80U/ml Interferon-gamma (Sigma-Aldrich, St. Louis,
MO) at 33◦C as permissive/undifferentiated condition. The cul-
tures were transferred to 37◦C and incubated in the media above
without IFN-γ and allowed to differentiate for 14 days. Differ-
entiated murine podocytes and glomerular endothelial cells were
used in the experiments. Mouse NKT cell lines Vα14+DN32.D3
and N38-3C3, and CD1d-specific N37-1A12 (Vα5+) were pre-
viously described (Lantz and Bendelac, 1994; Brutkiewicz et al.,
1995; Burdin et al., 1998; Roberts et al., 2002) and were cultured
in Iscove’s modified Dulbecco’s medium (IMDM) (Life Tech-
nologies) supplemented with 5% FBS and 2mM L-glutamine.
Murine L cells transfected with wild-type Cd1d1 cDNA (L-
CD1d) or with control vector (L-vector) were described (Chen
et al., 1997; Webb et al., 2008) and cultured in Dulbecco’s Modi-
fied Eagle Medium (DMEM) (Life Technologies) supplemented
with 2mM L-glutamine (Lonza BioWhittaker, Walkersville,
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FIGURE 1 | Delay in Stx2-induced pathology in NKT cell
deficient mice. (A) Percent survival of WT (n = 5) and CD1KO
(n = 5) after Stx2 injection is plotted. Log-rank (Mantel-Cox) test,
p = 0.0042. (B) Percent weight change of WT (n = 5) and CD1KO
(n = 5) after Stx2 injection is plotted. Error bars are standard
deviation. Two-Way ANOVA followed by Bonferroni test, *p < 0.05.
(C) BUN value of each mouse are plotted from WT (n = 5 per
time point) and CD1KO (n = 3 per time point). One-Way ANOVA
followed by Tukey test, *p < 0.05 WT compared to 0 h, #p < 0.05
CD1KO compared to 0 h. (D) Urinary albumin of WT (n = 2–9 per
time point) and CD1KO (n = 4–8 per time point) are plotted for
each urine sample obtained at indicated time points. One-Way
ANOVA followed by Tukey test, *p < 0.05 WT compared to 0 h,
#p < 0.05 CD1KO compared to 0 h. (E) Averages of plasma
concentration of WT (n = 5 per time point) and CD1KO (n = 3 per
time point) from matching samples to (C) are shown. Error bars
are standard deviation. One-Way ANOVA followed by Tukey test
and no significance was detected. (F) Averages of urinary protein
concentration of WT (n = 2 to9 per time point) and CD1KO (n = 4
to 8 per time point) from matching samples to (D) are shown.
One-Way ANOVA followed by Tukey test, *p < 0.05 WT compared
to 0 h, #p < 0.05 CD1KO compared to 0 h.
MD), 10% FBS (HyClone) and ciprofloxacin (EMD Millipore,
Billerica, MA).
Purification of Stx2 with LPS Removal
Purification of Stx2 was kindly provided by Dr. Anne Kane
(The Phoenix Lab at Tufts Medical Center, Boston, MA)
(Donohue-Rolfe et al., 1989; Stone et al., 2012). LPS was removed
from purified Stx2 by Detoxi-gel from Thermo Fisher Scientific
(Rockford, IL, USA) by the manufacturer’s protocol. A phosphate
buffer saline (PBS)-eluted and 0.2µm filter sterilized Stx2 frac-
tion was tested by Limulus amebocyte lysate assay with detection
limit>0.03 endotoxin unit (EU)/ml (Pyrotell, Associates of Cape
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Cod Incorporated, East Falmouth, MA, USA). Stx2 solutions
for culture experiment and mouse injection were determined to
contain less than 0.03EU/ml of endotoxin.
BUN Measurement for Renal Failure Evaluation
EDTA-blood was centrifuged at 3000 g for 15min at 4◦C. Plasma
was separated from buffy coat and used for BUN assay. BUN
assay was performed following directions of the Urea Assay
kit (Abnova Taiwan Corporation, Taipei City, Taiwan) with
slight modification; plasma was diluted in molecular grade water
and samples were incubated for 40min at room temperature,
and incubated with agitation for 10min at room temperature.
Absorption at 520 nm was read using a microplate reader (Syn-
ergy HT, Biotek, Winooski, Vermont). Concentration of Urea
(mg/dL) was calculated based on a Urea standard curve. Urea
concentrations were converted to BUN as stated in the manual:
BUN (mg/dL)= [Urea (mg/dL)]/2.14.
ELISA
Cytokine levels in kidney cell lysates from WT or CD1KO mice
treated with Stx2 for the indicated time periods were deter-
mined by ELISA. A half kidney was homogenized with 1ml
RIPA buffer consisting 50mMTris, 150mMNaCl, 1% igepal CA-
630, 0.5% deoxycholic acid supplemented with protease inhibitor
cocktail and 1mM phenylmethylsulfonyl fluoride (PMSF) (all
from Sigma-Aldrich). After centrifugation, resulted supernatant
(lysate) was used for the assay. Mouse IL-2 ELISA kit from BD
Biosciences (San Jose, CA) or mouse IFN-γ, IL-4 and IL-17
ELISA Max™ kits from BioLegend (San Diego, CA) were pur-
chased and used as per the manufacturer’s directions. Kidney
lysates were loaded onto ELISA plates in triplicate and cytokine
concentrations were determined using a standard curve. The
obtained concentrations were normalized to total protein in the
sample and represented as pg of cytokine permg total protein.
Urine Analyses
Urine was collected from mice every 12 h starting at 0 h (prior to
Stx2 injection) or the time of tissue harvesting. In the case of dis-
section, mice were euthanized by CO2 inhalation and urine was
collected directly from the bladder using a needle and syringe. An
equal volume of urine (5µl) per lane was analyzed by SDS-PAGE
with coomassie brilliant blue (CBB) stain along with known
amount of bovine serum albumin (BSA). After densitometry of
66 kDa band (albumin) (Sekine et al., 2012), the amount (µg)
per 5µl urine was calculated from BSA standard curve. The pro-
tein concentration of urine was analyzed by BCA assay (Thermo
Fisher Scientific Inc. Rockford, IL).
Immunofluorescence Stain of Stx2-Treated Cells
Vero cells, differentiated podocytes and differentiated endothe-
lial cells were trypsinized and seeded on glass bottom petri dishes
(MatTek, Ashland, MA). After the attachment, cells were incu-
bated with 20 nM Stx2 for 5 and 15min at 37◦C. No toxin
added cells (0min) were used as toxin negative controls. After
the incubation, dishes were placed on the ice, and washed
with ice cold phosphate-buffered saline (PBS, Cellgro). Cells
were fixed with 4% parafolmaldehyde (PFA, Sigma-Aldrich)/PBS,
washed and blocked with 3% Bovine serum albumin (BSA,
Sigma-Aldrich)/PBS. In order to detect cell surface localization,
cells were not permeabilized. Anti-Gb3 rat monoclonal antibody
(clone 38–13, Immunotec/Beckman Coulter, Brea, CA) diluted
in 1% BSA/PBS incubation was followed by PBS wash and anti-
rat IgM-AlexaFluor488 (Life Technologies). After wash, anti-
Stx2A mouse monoclonal antibody (11E10, ATCC) diluted in
1% BSA/PBS was followed by PBS wash and anti-mouse IgG-
AlexaFluor647 (Life Technologies). Nuclei were stained with 4’,6-
diamidino-2-phenylindole (DAPI, Life Technologies). Identical
dishes were made one for confocal microscopy observation and
another for 3D STORM-TIRF observation. Cells were kept in PBS
at 4◦C until microscopic observation.
Confocal Microscopy
Confocal microscope LSM510 (Carl Zeiss, Thornwood, NY) with
Argon (488 nm, 25mW), Helium Neon (633 nm, 6mW) and
MaiTai (710 nm, 1.5 W) lasers was used to visualize AlexaFluor-
488, -647, DAPI and differential interference contrast microscopy
(DIC). LSM 5 Image Browser was used to acquire and analyze
images.
Three Dimensional STORM-TIRF Imaging and
Analysis
Buffer of the cells was changed to STORM-imaging buffer con-
sisting 50mM Tris-HCl (pH 8.0), 10mM NaCl, 10% glucose,
5.6mg/ml glucose oxidase, 0.17mg/ml catalase, 100mM MEA
(cysteamine) (all from Sigma-Aldrich). A 256 × 256 pixel field
that includes approximately one cell per field was imaged at a
time. TIRF degree of 2660 was used in perfect focus 3D STORM
setting upon sample bleaching for the certain angles below and
above indicated TIRF angle. The sample bleaching is in order to
get rid of unspecific signals. Argon (488 nm) and Helium Neon
(647 nm) lasers were used in 100% power at acquisition in order
to activate all possible fluorescence molecules. A total of 10,000
signals were collected per image. InNikonNIS-Elements AR soft-
ware was used to acquire and analyze collected STORM-TIRF
images. Diameter of one fluorescence molecule was 0.01µm.
Twelve 488/647 double positive clusters were measured for the
size in molecules. The 488 cluster size was calculated as 39.25 ±
14.97 fluorescence molecules per cluster and the 647 cluster
size was calculated as 42.83 ± 17.93 fluorescence molecules per
cluster. An entire cell was sectioned in 50 nm z-steps (z-slices)
from extracellular to intracellular in the range between -500 and
500 nm, and 488/647 double positive objects that fulfill inten-
sity and area size of the positive clusters in each z-slices were
accordingly counted.
In vitro NKT Activation Assay
Differentiated murine podocytes and endothelial cells were
treated with or without 1 nM Stx2 for 1 h at 37◦C. Cells (5 ×
105 per well) were washed extensively (three times) and loaded
with 100 ng/ml of α-GalCer purchased from Avanti Polar Lipids
(Alabaster, AL) for 2 h at 37◦C in IMDM supplemented with 5%
FBS and 2mM L-glutamine from Life Technologies (Carlsbad,
CA). After this lipid antigen loading step, cells were washed again
and co-cultured with DN32.D3 (type I), N37-1A12 (type II) or
Frontiers in Microbiology | www.frontiersin.org 4 April 2015 | Volume 6 | Article 262
Obata et al. NKT cells accelerate Stx2 pathology
N38-3C3 (type I) NKT cell hybridomas (5 × 104 per well) in the
same medium. Medium alone and L-vector, a mouse fibroblast
cell line transfected with empty vector were used as negative con-
trols. L-CD1d, a mouse fibroblast cell line transfected with CD1d
and known to present an unknown, endogenous, strongly acti-
vating antigen to NKT cells was used as a positive control. The
coculture was set up in triplicate in 96-well microtiter plates for
20 h at 37◦C. Following the coculture, supernatants were har-
vested and IL-2 levels, which are indicative of NKT cell activa-
tion were measured by ELISA, as described above (Webb et al.,
2006).
Flow Cytometry
Cells were stained in staining buffer (PBS containing 0.5% BSA
and 2mM EDTA) for 30min at 4◦C with phycoerythrin (PE)-
conjugated anti-CD1d antibody (clone 1B1) or the respective
isotype control from BDBiosciences in accordance with theman-
ufacturer’s directions. After staining, cells were washed three
times with staining buffer and analyzed immediately by flow
cytometry. Data were collected on an LSR II from BD Bio-
sciences and analyzed using FCS Express Version 3 from De
Novo Software (Los Angeles, CA).
Statistical Analyses
One-Way ANOVA followed by Tukey test was performed with
the time course series samples compared to 0 h value. P-values
less than 0.05 was determined as significant. Two-Way ANOVA
followed by Bonferroni test was used for compare two strains
(WT vs. CD1KO), and p-values less than 0.05 was determined as
significant. All statistical analyses were performed using Graph-
Pad Prism 5.04 software (GraphPad Software, Inc., La Jolla,
CA).
Results
Stx2-Induced Pathologies were Delayed in
CD1KO Mice
In order to determine whether NKT cells contribute to Stx2-
mediated disease, C57BL/6 (WT) mice and CD1KO (NKT cell
deficient) mice were treated with Stx2 (i.p.,) andmortality, weight
loss, BUN, urinary albumin, urinary protein, and serum pro-
tein were measured (Figure 1). The survival of CD1KO mice
injected with Stx2 was prolonged twice as much compared to
WT (Figure 1A). Similarly, Stx2-induced weight loss occurred
more rapidly in WT mice compared to CD1KO mice, with 10%
weight loss occurring in WT mice by 48 h post-treatment, while
in CD1KO mice it did not occur until 72 h (Figure 1B). Dif-
ferences were also detected in renal function. BUN was signifi-
cantly increased in WT mice 60 h after Stx2 injection, whereas
in CD1KO mice, significant increase of BUN was seen after
72 h (Figure 1C). Plasma total protein concentrations in both
WT and CD1KO did not change throughout the time course
(Figure 1E) emphasizing the significance of BUN increase in Stx2
injected animal. Furthermore, urinary albumin was increased
after 60 h of Stx2 injection in WT, whereas it increased after 84 h
in CD1KO (Figure 1D). Total urinary protein was reduced in
WT 24 h post Stx2 injection, and the reduction was delayed in
CD1KO mice, as it occurred after 60 h (Figure 1F). These delays
observed in CD1KO strongly suggest NKT cell involvement in
the acceleration of Stx2 pathology.
Stx2-Induced Renal Cytokine Response is
Delayed in CD1KO Mice
Given the delay in Stx2-pathologies in CD1KO mice, we sus-
pected the induction of NKT cell-associated inflammation in
kidney. NKT cells produce cytokines such as IL-2, IL-4, IFN-γ,
and IL-17. Kidney lysates of Stx2-injected mice were analyzed for
these cytokines (Figure 2). InWTmice, IL-2, IL-4, IFN-γ, and IL-
17 showed increase after 8 h and peaked at 36–48 h following Stx2
injection. In line with previous markers of Stx2-mediated pathol-
ogy in CD1KOmice, significant increases in these cytokines were
noted later at 60 h. These data suggest that NKT cell activa-
tion contributes to accelerate Stx2 renal pathology by promoting
inflammation.
Stx2 Binds to Mouse Renal Glomerular Cells
In vitro
In kidney, the first cell types that NKT cells as well as Stx2
may encounter are glomerular cells, such as endothelial cells and
podocytes. We tested the possibility of Stx2 directly interact-
ing with murine glomerular cells by using sensitive fluorescence
imaging methods. Murine glomerular podocytes and Vero cells
were incubated with Stx2 and the localization of Stx2 (red) and
the receptor Gb3 (green) was observed by confocal microscopy.
Without Stx2, podocytes had none to minimum level of red,
whereas Gb3 was clearly positive (Figure 3A, 0min) and the
result was similar in Vero cells (Figure 3B, 0min). In all NKT cell
hypbridomas tested, Gb3 immunofluorescence was undetectable
(data not shown). Stx2 incubation of 5 and 15min resulted in
cell surface Stx2 localization in both podocytes and Vero cells
(arrowheads, Figures 3A,B, 5 and 15min). To observe the pre-
cise contact of Stx2 and Gb3 molecules at the plasma membrane,
3D STORM-TIRF was utilized. In 3D STORM-TIRF observation,
occurrences of Stx2 (red) and Gb3 (green) contact can be visual-
ized as yellow clusters (Figure 3C, whole cell view). The occur-
rence of yellow clusters in Vero cells, podocytes and endothelial
cells are shown in Table 1. Because the whole cell view looks at
all signals from the top of z-sections and STORM detects individ-
ual fluorescence as single molecule, a close up of a yellow cluster
shows more precise three dimensional positioning of Stx2 (red)
and Gb3 (green) (Figure 3C, yellow cluster view). The 360
◦ of a
yellow cluster view is presented as a movie (Supplemental Fig-
ure 1). In the yellow cluster depth view, the colors are assigned
according to the depth of the molecules from outside of the
cell as Red (distance -500 nm from plasma membrane) to inside
of the cells as blue (distance 500 nm from plasma membrane)
(Figure 3C, yellow cluster depth view, 360◦ appearance in Sup-
plemental Figure 2). For example, 0min sample in which Stx2
is not added, a yellow cluster that occurs occasionally as back-
ground is shown in the depth view that colored as green to yellow
(membrane to extracellular). In the samples of 5 and 15min,
representative yellow clusters are blue to green (intracellular to
membrane) in the depth view. To show the distribution of yellow
clusters along with the depth scale, the yellow clusters from each
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FIGURE 2 | CD1KO mice show delayed renal cytokine release
following treatment with Stx2. (A–D) WT (n = 3 per time point) or
CD1KO (n = 3 per time point) mice were treated with Stx2 for the indicated
time periods. Kidney lysates from both treatment groups at the indicated
time points were analyzed by ELISA and (A) IL-2, (B) IL-4, (C) IFN-γ and
(D) IL-17 concentrations were determined. Results were normalized to total
protein and have been represented as pg of cytokine permg total protein.
One-Way ANOVA followed by Tukey test, *p < 0.001 vs. WT 0h,
$p < 0.001 vs. WT 36 h, @p < 0.05 vs. WT 36 h and #p < 0.001 vs.
CD1KO 0h.
z-section of an entire cell were counted, and shown in contact
count graphs (Figure 3C, contact count). The graph plots depth
information in x-axis, and cluster counts in y-axis. The results
depicts the distribution of Stx2/Gb3 double positive clusters that
the longer Stx2 was incubated with the cells, the more cluster
counts were obtained and the clusters internalized deeper in the
cells. Murine glomerular endothelial cells and Vero cells showed
similar results (Supplemental Figure 3). Negative controls such as
fluorescence-conjugated secondary antibodies are omitted, had
only residual signals of AlexaFluor 647 or 488, and the yel-
low cluster observation was none to minimum (Supplemental
Figure 4).
Stx2-Treated Mouse Glomerular Cells Activate
NKT Cells
CD1d-restricted NKT cells can be activated by recognizing lipid
antigen that is presented in the context of CD1d molecules that
are expressed on antigen presenting cells. The ability of Stx2-
treated murine renal glomerular cells to induce NKT cell activa-
tion was measured by ELISA. Podocytes (Figure 4A) or endothe-
lial cells (Figure 4B) were incubated with or without Stx2, and
αGC was added as a lipid antigen, then co-cultured with NKT
cells. Stx2-treated cells with αGC induced higher levels of IL-2,
compared to the no toxin control in the presence of an exogenous
antigen, αGC (p < 0.001). Without αGC, both Stx2-treated
and non-treated cells did not induce IL-2 production by NKT
cells. The positive control, mouse L-cells stably transfected with
mCD1d1 (L-CD1d) induced IL-2 production in all NKT cell
hybridomas. In order to determine whether an increase in NKT
activation in Stx2-treated cells is due to an increase in CD1d sur-
face expression, flow cytometry was performed with podocytes
(Figure 4C) or endothelial cells (Figure 4D). Addition of Stx2
did not change the surface expression of CD1d in podocytes or
endothelial cells, suggesting an increase in NKT activation in
Stx2-treated renal cells is not due to an increased the levels of
CD1d.
Discussion
We demonstrated for the first time that NKT cells accelerate
Stx2-pathology in mice. Mice with normal numbers of NKT cells
had higher levels of cytokine early after treatment IL-2, IL-4,
IFN-γ, and IL-17 in mouse kidney with subsequent renal fail-
ure as well as urine abnormality. In STEC-HUS patients, serum
levels of IL-2, IL-4, and IFN-γ were similar to the healthy con-
trol group (Shiraishi et al., 2008), however the tissue cytokine
levels have not been studied. In the non-human primate that
maybe the closest model to humans, IL-2, IL-4, IFN-γ, and
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FIGURE 3 | Stx2 interacts with murine glomerular renal cells
in vitro. (A) Murine podocytes or (B) Vero cells were incubated with
20 nM Stx2 for 0 (no toxin), 5 and 15min at 37◦C. Stx2 was labeled
with monoclonal antibody 11E10 followed by anti-mouse IgG-AlexaFluor
647 (pseudo colored red) and Gb3 was labeled with monoclonal
antibody 38.13 followed by anti-rat IgM-AlexaFluor 488 (green). Nuclei
were stained with DAPI (blue). Samples were observed with confocal
microscopy. Representative cells that are chosen from each time point
group are shown. Bars indicate 10µm. Arrowheads point
Stx2-AlexaFluor 647 positive cells. (C) Murine podocytes were incubated
with 20 nM Stx2 for 0 (no toxin), 5 and 15min at 37◦C and labeled as
above. Samples were visualized with 3D STORM-TIRF microscopy and
analyzed using Nikon Elements software. Whole cell view presents
representative cells from each time point. Bars are 10µm. Yellow spot
view presents highly magnified and three dimensionally shown yellow
cluster (red = Stx2-Alexa647, green = Gb3-Alexa488 and yellow = red
and green overlapping pixels). Bars are 100 pixels (px). Yellow cluster
depth view depicts the intra or extracellular depth of the yellow cluster.
The color-coded depth scale at the left differentiate the distance (nm)
from the focus plane (0 nm, green). Blue represents intracellular (up to
500 nm) whereas red represents extracellular (up to -500 nm). Contact
count given in the graphs presents amount and depth distribution of
green and red contact of a whole cell. The color-coded depth scale at
the bottom indicates intracellular (blue) to extracellular (red).
IL-17 were not detectable after Shiga toxins injection (Stearns-
Kurosawa et al., 2010). In this model, serum IL-12/23 was also
not detectable after Shiga toxins injection, but IL-12 mRNA was
upregulated in kidneys (Stearns-Kurosawa et al., 2013). This
suggests that there is a renal specific inflammation after Shiga
toxins injection. NKT cells also produce RANTES and MIP1-α
(Chang et al., 2007), which have been implicated in the mouse
model of HUS (Keepers et al., 2007; Sauter et al., 2008). NKT cells
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produce cytokines that can recruit or activate neutrophils (Naka-
matsu et al., 2007) and macrophages (Kronenberg and Gapin,
2002), and they are also implicated in Stx2-associated mice renal
pathology (Keepers et al., 2007; Roche et al., 2007). Thus, Stx2-
associated NKT activation in the kidney may explain rapid renal
recruitment of neutrophils and macrophages to induce further
inflammation.
In vitro, we showed that murine renal glomerular podocytes
and endothelial cells express functional CD1d. NKT cells were
able to recognize the lipid antigen αGC:CD1d complexes on renal
cells and this lead to increased levels of IL-2 when renal cells were
TABLE 1 | Cells with yellow clusters (488/647 positive clusters) in 3D
STORM-TIRF observation.a
0min (%) 5min (%) 15min (%)
Vero cell 0/3 (0) 2/4 (50) 2/12 (17)
Podocyte 2/3 (66)b 1/3 (33) 2/8 (25)
Endothelial cell 2/3 (66)b 2/3 (66) 2/3 (66)
aWhen more than one yellow cluster is observed in one cell, it is counted as a yellow
cluster positive cell. However, the frequency or the total numbers of yellow clusters in the
cell or the distribution of the clusters, whether they are intracellular or extracellular, is not
reflected in this table. Examples of numbers and distributions of yellow clusters are shown
in Figure 3C.
b488/647 overlap clusters are minimum number and/or extracellular.
treated with Stx2. Activation of NKT cells were only seen in the
presence of αGC, this suggests murine renal cells do not present
an activating self-antigen (endogenous lipid antigen) after 1 h of
Stx2 treatment. However, this may be the result of the short treat-
ment time (1 h) and longer incubations with Stx2 might result in
change in the repertoire of lipid antigens. Furthermore, expres-
sion levels of CD1d in both types of renal cells were not altered
following treatment with Stx2. The mechanism by which Stx2
treatment leads to enhance CD1d-mediated NKT cell activation
needs further investigation. In bacterial infection, lipopolysac-
charide (LPS) has been shown to interact with toll-like receptor
4 (TLR4) of dendritic cells (DCs) and induce NKT cell activation
in the absence of an activating bacterial antigen, but is depen-
dent on the secretion of IL-12 by DC (Brigl et al., 2003; Mattner
et al., 2005). As our Stx2 fraction is free of LPS, therefore LPS-
induced IL-12 is not responsible for these changes in NKT cell
responses; however, our data indicates that Stx2 may induce a
co-stimulator(s) factor in renal cells to activate NKT cells.
We presented evidence showing the direct interaction of
Stx2 with murine podocyte Gb3 in a single molecule imag-
ing analysis known as 3D STORM-TIRF. In traditional light
microscopy, the resolution is limited by diffraction and the ability
of the microscope to separate objects that are more than 200 nm
apart. Whereas, electron microscopy gives higher resolution in
nanometer ranges with a tradeoff of longer processing of sam-
ples. The STORM technique enables fluorescence imaging to be
FIGURE 4 | Stx2-treated murine glomerular renal cells are able to
activate NKT cells in vitro. (A) Murine podocytes or (B) murine
glomerular endothelial cells were treated with (stx) or without (untx) Stx2,
washed and incubated either with or without 100 ng/ml of αGC for 2 h.
These antigen loaded cells were then washed and cocultured with
DN32.D3, N37-1A12 or N38-3C3 NKT cell hybridomas for 20 h. IL-2
was measured in the supernatant by ELISA as readout for NKT cell
activation. Medium alone and empty vector-transfected L-cells (L-vector)
were used as negative controls, and CD1d-transfected L-cells (L-CD1d)
was used as a positive control. (C) Murine podocytes and murine
glomerular endothelial cells were incubated with (bold line) or without
(dashed line) Stx2 and stained with PE-conjugated anti-CD1d antibody
and cell surface expression of CD1d was determined by flow cytometry.
An isotype control Ab-PE served as a negative control (gray). (D)
L-vector and L-CD1d were used as negative and positive controls,
respectively.
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close to the resolution obtained using electron microscopy by
calculating the fluorescence source to its exact position and 3D
function allows precise depth information of molecules that are
close to plasma membrane in conjunction with TIRF function.
To study cell types that are resistant to Shiga toxins but respond
by other biological measures, like cytokine production by Stx1-
treated human monocytes (Ramegowda and Tesh, 1996), this
state of the art imaging technique is an effective tool to provide
evidence of the direct interaction of toxin binding to its receptor.
In summary, our data support a model where NKT cells con-
tribute to Stx2-associated renal pathology and lethality. Further-
more, our data suggests that Stx interactions with glomerular
cells may promote CD1d-mediated NKT cell activation. There-
fore, we hypothesize that NKT cells may accelerate progression to
renal failure during STEC infection through Stx2-effects on renal
endothelium and podocytes that potentiate NKT-cell activation
and result in increased inflammatory signaling. If NKT cells do
potentiate inflammation and renal failure during STEC infection,
inhibition of NKT-cell activation may be a therapeutic strategy
to prevent or delay the progression of STEC-associated systemic
disease such as HUS.
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